Dr. Mitchell K. Spinnell, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 679
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: State University of New York at Buffalo School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NJ license 25MA06936400
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Englewood Hospital and Medical Center Englewood, NJ
Medical groups
- Medical Associates of Englewood PC (540 clinicians)
- Allied Digestive Health LLC (286 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 679
- Services billed
- 1,483
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 226 | 170 |
| Established patient office or other outpatient visit, 20-29 minutes | 222 | 173 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 135 | 132 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 130 | 59 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 116 | 114 |
| New patient office or other outpatient visit, 30-44 minutes | 55 | 55 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 53 | 51 |
| Biopsy of large bowel using a flexible endoscope | 48 | 48 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 38 | 38 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Englewood Cliffs, NJ | 429 |
| Pantoprazole Sodium Other prescribers in Englewood Cliffs, NJ | 136 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 110 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Englewood Cliffs, NJ | 109 |
| Esomeprazole Magnesium Other prescribers in Englewood Cliffs, NJ | 63 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Englewood Cliffs, NJ | 62 |
| Mesalamine Other prescribers in Englewood Cliffs, NJ | 59 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in Englewood Cliffs, NJ | 57 |
| Ursodiol Other prescribers in Englewood Cliffs, NJ | 43 |
| Famotidine Other prescribers in Englewood Cliffs, NJ | 42 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 87 payments worth $1,665 in total to this clinician.
| AbbVie Inc. | $595 |
|---|---|
| Janssen Scientific Affairs, LLC | $237 |
| Takeda Pharmaceuticals U.S.A., Inc. | $122 |
| Janssen Biotech, Inc. | $118 |
| Aimmune Therapeutics, Inc. | $55.92 |
| Celltrion USA Inc. | $54.01 |
| Madrigal Pharmaceuticals | $53.23 |
| Ferring Pharmaceuticals Inc. | $50.91 |
| Food and Beverage | $1,645 |
|---|---|
| Grant | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jan 15, 2025 | Grant RINVOQ · IMMUNOLOGY | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $11,849 in research payments for these studies, mostly to the institutions running them.
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company · Active, not recruiting · NCT04232553
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.